Lobbying Update: $70,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed
A new Lobbying Disclosure Act filing revealed that COHERUS BIOSCIENCES INC. (CHRS) spent $70,000 on lobbying in Q4 2026, focusing on issues such as oncology, domestic drug production, and supply chain security. This update also highlights recent hedge fund activity, with significant changes in institutional investor holdings, and provides an overview of recent "Buy" ratings and price targets from Wall Street analysts for CHRS.
Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
Coherus Oncology is reducing its workforce by 30% as part of a reorganization to focus its pipeline efforts primarily on esophageal cancer, deprioritizing other indications. Separately, Gyre Therapeutics is also undergoing layoffs following its acquisition of Cullgen, resulting in increased personnel and severance costs. Both biotechs are restructuring their operations, with Coherus aiming to significantly lower its quarterly core cash burn.
Earnings call transcript: Coherus BioSciences posts Q3 2026 revenue miss, shares rise
Coherus BioSciences reported a Q3 2026 revenue miss but matched EPS expectations, with shares rising due to investor focus on pipeline developments and cost reduction efforts, including a 30% workforce reduction. The company is strategically prioritizing esophageal cancer for its tagmokitug development and expects LOQTORZI revenues to grow, despite a sequential miss on internal targets. Coherus aims to achieve financial self-sustainability by the end of 2027 through these strategic shifts and non-dilutive funding options.
Coherus BioSciences Q3 Results: Loss narrows 39% YoY, sales miss estimates
Coherus BioSciences reported a narrower Q3FY26 loss of $(0.20) per share, beating estimates, but revenue of $14.274 million missed expectations despite a 23.36% YoY increase. The company announced a 30% headcount reduction to save $6-7 million quarterly, shifting its strategic focus to esophageal cancer for its Tegmo Ketog program. Cash reserves provide a runway of less than 12 months, highlighting the critical need for successful LOQTORZI commercialization and cost management.
Coherus BioSciences Q3 2026 Earnings Call Transcript
Coherus BioSciences reported Q3 2026 net sales of $14 million, falling short of their 10-15% target despite 25% year-over-year growth. The company announced a 30% headcount reduction to save $6-7 million quarterly and is strategically focusing its Tegmo Ketog program on esophageal cancer for accelerated FDA approval and ex-US partnerships. Coherus aims to boost LOQTORZI revenues to $25-$30 million quarterly by 2027 to cover core costs and achieve financial sustainability.
Coherus Oncology, Inc. (CHRS) stock price, news, quote and history
Coherus Oncology, Inc. (CHRS) saw its stock price close at $0.8301 on October 30, with a slight after-hours gain. The biopharmaceutical company, which changed its name in May 2025, focuses on developing immunotherapies for cancer and has a market capitalization of $128.251 million. Analysts have an average 1-year target estimate of $7.75 for the stock.
Coherus Biosciences stock rating maintained at Outperform by Oppenheimer
Oppenheimer has reiterated an Outperform rating on Coherus Biosciences (NASDAQ:CHRS) stock, maintaining its $10.00 price target. The firm's decision follows an update on Coherus's tagmo across tumor indications, where early efficacy signals were reported for tagmo combined with tori in first-line and second-line esophageal squamous cell carcinoma. Despite modest expectations, Oppenheimer found sufficient evidence to support the development path for tagmo, focusing on esophageal squamous cell carcinoma.
Coherus Biosciences stock rating maintained at Outperform by Oppenheimer
Oppenheimer has reiterated an Outperform rating for Coherus Biosciences (NASDAQ:CHRS) stock, maintaining a $10.00 price target. The firm commented on the company’s update regarding its drug 'tagmo' across tumor indications, noting early efficacy signals in esophageal squamous cell carcinoma. Despite a slightly delayed timeline and mixed results from other CCR8 programs, Oppenheimer found sufficient evidence to support the drug's path forward, with regulatory discussions now focused on esophageal squamous cell carcinoma pathways.
Coherus Oncology Reports 89% Response Rate in Early ESCC Study
Coherus Oncology presented interim clinical data for tagmokitug, an investigational therapy, showing an 89% overall response rate in early esophageal squamous cell carcinoma (ESCC) patients. The company plans to expand cohorts and engage with the FDA to discuss potential regulatory pathways. This therapy, in combination with toripalimab, also demonstrated activity in other solid tumors like head and neck cancer, upper GI adenocarcinomas, and colorectal cancer.
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
Coherus Oncology announced compelling interim clinical data for tagmokitug, its investigational CCR8 antibody, in combination with toripalimab, showing encouraging anti-tumor activity across multiple solid tumors, particularly in esophageal squamous cell carcinoma (ESCC). In front-line ESCC, the treatment achieved a confirmed overall response rate (cORR) of 75% irrespective of PD-L1 status, and 100% in PD-L1 positive patients. The company plans to expand enrollment in ESCC cohorts and continue evaluating the therapy's efficacy and safety.
Coherus Oncology stock trades 61.45 percent below its 52-week high
Coherus Oncology (CHRS) stock is trading 61.45 percent below its 52-week high of USD 2.62, with a market capitalization of USD 156.0 million as of October 23, 2026. The company reported a second-quarter 2026 revenue of USD 14.31 million, a 39.53 percent increase year-over-year. Coherus is a commercial-stage oncology company with an approved PD-1 inhibitor and clinical candidates in its pipeline.
Coherus schedules October 28 webcast for Coherus Oncology stock
Coherus Oncology has scheduled a webcast for October 28, 2026, to present interim clinical data for its Tagmokitug program, a cytolytic CCR8 antibody. The webcast will discuss the program with management and clinical experts. The company recently reported a 39.61% increase in second-quarter 2026 revenue, reaching USD 14.31 million.
Coherus Oncology schedules October 28 webcast for Coherus Oncology stock
Coherus Oncology (CHRS) has scheduled a webcast for October 28, 2026, at 4:30 p.m. EDT to disclose interim clinical data for its Phase 1b antibody candidate, Tagmokitug, which targets CCR8 in advanced solid tumors. The company's stock was priced at USD 0.99 on October 16, 2026, down 7.48% from its previous close, with a market capitalization of USD 153.0 million. This webcast will focus on clinical pipeline progress rather than financial updates, as the stock remains near its 52-week low.
Coherus Oncology stock sits at EUR 0.93 with a price-to-earnings ratio of -1.02
Coherus Oncology (CHRS) stock was trading at EUR 0.93 with a price-to-earnings ratio of -1.02 on October 15, 2026. The company had a market capitalization of USD 161.5 million, and its 52-week range was between USD 0.97 and USD 2.62, with the latest quote above its yearly low. Coherus Oncology is a commercial-stage oncology business listed on Nasdaq.
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Coherus Oncology, Inc. announced it will release interim clinical data for its tagmokitug development program, which evaluates the cytolytic CCR8 antibody with toripalimab in multiple solid tumors, on October 28, 2026. The company will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data, with key opinion leaders providing clinical perspectives. This webcast will be accessible via pre-registration and streamed on the "Investors" section of Coherus's website.
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Coherus Oncology, Inc. announced it will host a webcast on Wednesday, October 28, 2026, to release interim clinical data for its tagmokitug development program, evaluating a cytolytic CCR8 antibody with toripalimab in various solid tumors. Management and key opinion leaders will discuss the data from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time. Investors can register to access the live call and find archived webcasts and materials on the company's investor relations website.
Coherus BioSciences Share Price - CHRS, RNS News, Articles, Quotes, & Charts
This article provides an overview of Coherus BioSciences (NASDAQ: CHRS) share price, news, and market data. It highlights the company's focus on developing high-quality biosimilar therapeutics to expand patient access to medicines. The page also features recent news regarding FDA approvals and acquisitions related to Coherus BioSciences.
Coherus Oncology stock falls 5.38 percent in trading
Coherus Oncology's stock (CHRS) fell 5.38 percent to EUR 0.88 at Lang & Schwarz on October 8, 2026, despite a 39.53 percent increase in second-quarter 2026 revenue to USD 14.31 million. The company is focused on its oncology portfolio, including LOQTORZI, and is advancing other clinical programs. Analyst targets average USD 7.75, with the stock holding a USD 156.0 million market capitalization.
Coherus starts asset sale as H.C. Wainwright targets Coherus stock
Coherus Oncology has begun marketing its remaining legacy biosimilar assets and scheduled a distribution of contingent value rights to stockholders. H.C. Wainwright reiterated a Buy rating and set a USD 7.00 price target, highlighting the company's oncology transition. Despite improved revenue in Q2 2026, Coherus continues to experience GAAP net losses.
Coherus Oncology stock heads toward October 7 CVR distribution
Coherus Oncology (CHRS) stock is moving towards its October 7, 2026, CVR distribution date. The contingent value rights are tied to proceeds from the sale or licensing of legacy biosimilar assets, with their ultimate value dependent on completed transactions. Analysts have a strong buy consensus with an average price target significantly higher than the current Nasdaq price, despite the company's funding challenges and negative operating cash flow.
Coherus starts asset sale as Wainwright targets Coherus stock at USD 7.00
Coherus Oncology has begun marketing its remaining legacy biosimilar assets, including patents and intellectual property, with contingent value rights (CVRs) to be distributed to eligible shareholders. This move aims to generate additional proceeds without impacting their core oncology pipeline, as the company concentrates commercial efforts on LOQTORZI. H.C. Wainwright has maintained a Buy rating with a USD 7.00 price target, while analysts like Zacks see an average target of USD 7.75.
Coherus Oncology stock heads toward its October 7 CVR distribution
Coherus Oncology stock is approaching its Contingent Value Rights (CVR) distribution on October 7, 2026, which will be provided to shareholders of record from September 30, 2026, following the sale process of its biosimilar assets. The company reported improved Q2 2026 revenues and narrowed losses, but still faces uncertainties regarding the CVR proceeds and cash burn. Analysts maintain a "Buy" rating with a price target significantly higher than its current Nasdaq price, reflecting both growth potential in oncology and inherent risks.
Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun.
Coherus Oncology has initiated the sale process for its Legacy BioSim Assets, engaging Oppenheimer & Co. as financial advisor. Stockholders of record on September 30, 2026, will receive contingent value rights (CVRs) entitling them to a pro rata share of net proceeds from these sales or licensing agreements, with distribution on October 7, 2026. This move allows Coherus to monetize non-core biosimilar assets while focusing on its oncology pipeline and LOQTORZI.
Coherus BioSciences stock holds at USD 1.56 after a weak session
Coherus BioSciences (CHRS) stock closed at USD 1.56 on September 21, 2026, down 3.11% after a volatile trading session. The company reported 2025 revenue of USD 254.8 million, which remains a key reference point for investors. The stock's performance highlights the strong dependence of its valuation on updates to revenue, product sales, and the company's cash position, particularly given its operations in biopharmaceuticals.
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology (NASDAQ: CHRS) has declared a special dividend of non-transferable contingent value rights (CVRs) for stockholders of record as of September 30, 2026, with distribution on October 7, 2026. These CVRs entitle holders to a pro rata share of net cash proceeds from the monetization of its Legacy BioSim Assets, including patents, intellectual property, and royalties. The CVRs are non-transferable, will not trade publicly, and will expire on October 7, 2028, with no payment if no net proceeds are realized.
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com
This article announces the filing of a Form 8K by Coherus BioSciences Inc. for August 17th. It is a brief news item from Investing.com, providing no additional details or context beyond the filing date. The article is primarily composed of navigation and unrelated market data.
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology has announced a special dividend of Contingent Value Rights (CVRs) to shareholders, allowing them to receive net proceeds from the sale of its legacy biosimilar assets. This move completes the company's transformation into a focused, innovative immuno-oncology company. The CVRs will be non-transferable and will expire on October 7, 2028, with payments contingent on the successful monetization of these biosimilar assets.
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com
This article reports on a Form 8K filing by Coherus BioSciences Inc for August 17. The brief piece primarily serves as an announcement for the filing, linking to Reuters for more details. It also includes general market data and other popular news headlines.
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com
Investing.com reports that Coherus BioSciences Inc. filed a Form 8K for August 17th. The article provides this basic information along with market data, news headlines, and various financial tools available on the Investing.com platform. Coherus BioSciences (CHRS) stock is noted with a +16.52% change.
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com
This article reports on a Form 8K filing by Coherus BioSciences Inc. for August 17. The brief announcement from Investing.com indicates that the filing was made on this date. Coherus BioSciences Inc. (CHRS) saw a stock price change of -4.17%.
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology, Inc. (NASDAQ: CHRS) announced a special dividend of contingent value rights (CVRs) to its stockholders, allowing them to receive net proceeds from the sale of its remaining Legacy Biosimilar Assets. This move completes Coherus Oncology's transformation into a fully integrated, innovative immuno-oncology company. The CVRs are non-transferrable, will not be publicly traded, and will expire on October 7, 2028, unless proceeds are received from the asset sales.
Coherus BioSciences, Inc. (CHRS) stock price, news, quote and history
Coherus Oncology, Inc. (CHRS), formerly Coherus BioSciences, Inc., is a biopharmaceutical company focused on researching, developing, and commercializing immunotherapies for cancer. The article provides a detailed financial overview, including stock performance, key metrics like market capitalization and P/E ratio, and analyst ratings. It also lists the company's product pipeline, collaboration agreements, and comparative data with other biotechnology firms.
Coherus Oncology, Inc. (CHRS) Stock Price, News, Quote & History
This article provides a detailed overview of Coherus Oncology, Inc. (CHRS), including its current stock price, recent performance, company profile, and financial data. As of the market open, CHRS was trading at $1.3250, up 4.74%. The company, which recently changed its name from Coherus BioSciences, Inc., focuses on researching, developing, and commercializing immunotherapies for cancer, with products like UDENYCA and LOQTORZI.
Coherus Oncology, Inc. (CHRS) stock price, news, quote and history
Coherus Oncology, Inc. (CHRS) stock is trading at $1.3250, up 4.74%, with a market capitalization of $204.381 million. The biopharmaceutical company focuses on developing and commercializing immunotherapies for cancer, including products like UDENYCA and LOQTORZI. Analyst estimates a 1-year target price of $7.80 for the stock.
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall
Coherus Oncology Inc. reported a narrower-than-expected loss for Q2 2026, beating EPS estimates, but revenue fell slightly short of Wall Street's forecast, causing shares to fall in after-hours trading. The company's main oncology product, LOQTORZI, saw increased net sales and new patient starts, and Coherus is focused on ongoing clinical trials for tagmokitug and casdozokitug with anticipated data readouts later in 2026. Despite a mixed quarter with strong cost control but a revenue miss, the company maintains its full-year operating expense and LOQTORZI revenue guidance, expecting significant future growth for LOQTORZI.
Coherus Oncology Q2 2026 Earnings: LOQTORZI Growth Narrows the Loss
Coherus Oncology reported fiscal Q2 2026 net revenue of $14.3 million, a 40% increase year-over-year, driven primarily by LOQTORZI sales. The company narrowed its diluted loss per share to $0.22, largely due to LOQTORZI volume growth and reduced operating expenses. However, net cash used in operating activities increased to $62.1 million, and the company plans for several pipeline readouts in the second half of 2026.
Coherus BioSciences Inc (CHRS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Coherus BioSciences Inc (CHRS), detailing its volatility, financial risk, and investment risk. The company's risk assessment score is 2.69, ranking 118 out of 156 in the Pharmaceuticals industry, with a beta of 0.99 indicating underperformance in upward markets and smaller declines in downward markets. Key metrics like VaR, maximum drawdown, volatility, Sharpe Ratio, and liquidity indicators are presented to offer a comprehensive view of its investment risk profile.
Coherus BioSciences Inc (CHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Coherus BioSciences Inc (CHRS), detailing its price momentum score of 4.09 and its position within the Pharmaceuticals industry. It identifies key support and resistance levels for the stock, indicating suitability for range-bound swing trading. The analysis also includes a breakdown of various technical indicators and moving averages, offering a comprehensive view of the stock's current technical status.
Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 7.59 within the Pharmaceuticals industry. The company's P/E ratio is 0.86, significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Coherus BioSciences Inc (CHRS) Institutional Confidence
Coherus BioSciences Inc (CHRS) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 35.13%, marking a significant quarter-over-quarter decrease of 49.78%. James Simons is listed as the largest institutional shareholder, holding 0.22% of outstanding shares.
Coherus Biosciences Lobbying Profile, 2022
This OpenSecrets profile details the lobbying activities of Coherus Biosciences for 2022 and 2026. The company, which operates in the Pharmaceuticals/Health Products industry, spent $190,000 on federal lobbying in 2026. The report includes sections on hired firms, lobbyists, issues, agencies, and bills, with data updated as of July 23, 2026.
Lobbying Update: $95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed
A recent Lobbying Disclosure Act filing revealed that COHERUS BIOSCIENCES INC. engaged in $95,000 worth of lobbying during Q2 2026. The lobbying efforts focused on issues like oncology, Medicare coverage, domestic drug production, and supply chain security. Additionally, the article highlights recent hedge fund activity in CHRS stock, showing significant institutional investment.
CHRS|Coherus BioSciences Inc|Price:1.465|Chg%:+0.055
Coherus BioSciences Inc., now Coherus Oncology, Inc., is a commercial-stage oncology company focused on treating various cancers with its approved PD-1 inhibitor LOQTORZI and a pipeline of clinical candidates like CHS-114 and Casdozokitug. The article details the company's profile, including executives and financial data, highlighting UDENYCA as its primary revenue source. As of Q1 2026, 291 institutions hold CHRS shares, accounting for 35.13% of total shares.
Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings
The article provides a detailed breakdown of Coherus BioSciences Inc.'s (CHRS) shareholder structure, listing major individual and institutional holders. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) and shows trends in institutional shareholding and activity over several quarters. Finally, it lists ETFs with reported holdings of CHRS.
Coherus BioSciences Inc (CHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Coherus BioSciences Inc (CHRS) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and lists basic market data such as market capitalization and P/E ratio.
Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), segmenting its income by business product and geographic region as of April 6. The data shows that UDENYCA is the primary revenue driver, contributing 99.24% of the reported revenue, with the United States accounting for the majority of regional revenue.
Coherus BioSciences Inc (CHRS) Financial Health: Profitability & Balance Sheet Analysis
Coherus BioSciences Inc (CHRS) currently holds a financial score of 6.23, ranking 143 out of 155 in the Pharmaceuticals industry, indicating stable financial health but low operating efficiency. The company recently reported a quarterly revenue of $12.31M, marking a 61.99% year-over-year increase, and a net profit increase of 32.25% year-over-year. However, much of the detailed financial data, including cash and cash equivalents, total assets, and free cash flow, have not yet been disclosed by the company.
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020
Coherus BioSciences Inc (CHRS) shows relatively healthy fundamentals and high growth potential, though its stock price is expected to trend down in the medium term. The company's valuation is considered fair, ranking 97 out of 155 in the Pharmaceuticals industry, with strong institutional ownership. Analysts have rated it a Buy, with a highest price target of $7.25, indicating a significant upside potential despite recent weak market performance.
Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook
Coherus BioSciences (CHRS) stock is trading lower due to declining revenue from its biosimilar Udenyca and a challenging market. The company reported a significant revenue drop in 2023 and Q1 2024, alongside ongoing net losses, though Q1 2024 showed some narrowing of losses. Coherus is pivoting towards immuno-oncology with toripalimab and diversifying its biosimilar portfolio with products like Cimerli and Yusimry to offset Udenyca's erosion, while managing its cash reserves.
Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues
Coherus BioSciences (CHRS) stock is trading near recent lows due to declining biosimilar revenue and a strategic pivot towards oncology. The company reported a significant drop in fiscal 2023 revenue and widening net losses, reflecting intense competition in its legacy biosimilar products. Despite the financial headwinds, Coherus is investing heavily in its immuno-oncology pipeline, particularly toripalimab, aiming to establish a new growth-oriented franchise, although this transition carries execution risks and near-term profitability constraints.